Bolt Biotherapeutics, Inc. Logo

Bolt Biotherapeutics, Inc.

Clinical-stage biotech developing immuno-oncology therapies using the innate immune system.

BOLT | US

Overview

Corporate Details

ISIN(s):
US0977021049
LEI:
Country:
United States of America
Address:
900 CHESAPEAKE DRIVE, 94063 REDWOOD CITY

Description

Bolt Biotherapeutics is a clinical-stage biotechnology company developing immuno-oncology therapies to treat cancer. The company's approach leverages the innate immune system, particularly myeloid cells, to create a therapeutic anti-tumor response. Its proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) platform combines tumor-targeting antibodies with immune-stimulating agents. This technology is designed to repolarize tumor-supportive immune cells, such as macrophages, into tumor-destructive ones, while also activating the adaptive immune system. The company's pipeline includes multiple candidates generated from the ISAC platform and other novel approaches. A key candidate, BDC-3042, is a first-in-class Dectin-2 agonist antibody being evaluated in clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Bolt Biotherapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bolt Biotherapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bolt Biotherapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Arcus Biosciences, Inc. Logo
A clinical-stage biopharmaceutical company developing combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes treatments for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharmaceutical company developing medicines for cardiorenal and gastrointestinal diseases.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharmaceutical company enhancing medicines with its proprietary formulation technology.
United Kingdom
AREC
argenx SE Logo
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Develops bacteriophage therapeutics for antibiotic-resistant bacterial infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets in vitro diagnostic (IVD) tests for oncology and bacteriology.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
Clinical-stage biopharma developing oncology drugs for difficult-to-treat diseases.
United States of America
AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Biotechnology company developing RNAi therapies to treat intractable diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops and commercializes needle-free products for administering therapies.
United States of America
SPRY

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.